Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help ...

Chesapeake Utilities CFO Beth Cooper announces retirement, COO Jeff Sylvester named successor Accessibility StatementSkip NavigationDOVER, Del., March 24, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) today announced that executive vice president and chief financial officer Beth Cooper will retire on June 30, 2026, following 36 years with the Company. Senior vice president and chief operating officer Jeff Sylvester, who began his career with Chesapeake Utilities in 2004 serving in financ ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Company Overview - The Cooper Companies, Inc. (COO) is based in California and specializes in developing, manufacturing, and marketing products for contact lens wearers, with a market capitalization of $13.9 billion [1] - COO operates in two segments: CooperVision, which offers various types of contact lenses, and CooperSurgical, which provides fertility products, medical devices, contraception, and cryostorage services for women [1] Market Performance - COO stock has decreased by 20.9% from its 52-week high of $89.83 reached on December 5, 2025, and has declined 12.3% over the past three months, underperforming the Dow Jones Industrials Average, which fell by 2.4% during the same period [3][6] - Over the past 52 weeks, COO has seen a decline of 12.5%, while the Dow Jones Industrials Average has gained 13.2% [6] Recent Earnings Report - On March 5, COO reported mixed Q1 2026 earnings, with revenue increasing nearly 6% year-over-year to $1 billion, aligning with market estimates [7] - The adjusted EPS for the quarter rose by 20% from the previous year to $1.10, surpassing Wall Street expectations [7] - Despite the positive earnings, investor confidence waned due to weak organic revenue growth and slower business performance in the Asia Pacific region, leading to a 4.6% drop in stock price in the following trading session [7] Competitive Positioning - Compared to its peer Align Technology, Inc. (ALGN), COO has underperformed, with ALGN stock growing by 2% over the past year [8] - Sentiment towards COO remains moderately optimistic, with a consensus rating of "Moderate Buy" among 18 analysts and a mean price target of $90.81, indicating a potential upside of 27.8% from current levels [8]

Core Viewpoint - The Cooper Companies (COO) has experienced significant selling pressure, resulting in an 8.8% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential turnaround for the stock [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - COO's current RSI reading is 25.01, suggesting that the heavy selling pressure may be exhausting itself and a trend reversal could be imminent [5]. - The RSI helps investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for COO by 2.6% over the last 30 days, indicating a strong consensus among sell-side analysts and suggesting potential price appreciation in the near term [7]. - COO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [8].

Core Insights - The Cooper Companies reported total revenue of $1.02 billion for the quarter ending January 2026, reflecting a 6.2% increase from the previous year [4] International Revenue Analysis - EMEA contributed 27.6% of total revenue, amounting to $282.3 million, surpassing analyst expectations of $269.49 million with a surprise of +4.76% [5] - Asia Pacific generated $123.8 million, representing 12.1% of total revenue, falling short of the consensus estimate of $136.81 million with a surprise of -9.51% [6] Revenue Forecasts - Analysts project total revenue of $1.06 billion for the current fiscal quarter, a 5.4% increase year-over-year, with EMEA and Asia Pacific expected to contribute $267.79 million (25.4%) and $142.16 million (13.5%) respectively [7] - For the full year, total revenue is anticipated to reach $4.32 billion, a 5.6% increase from the previous year, with EMEA and Asia Pacific expected to account for $1.13 billion (26.2%) and $577.79 million (13.4%) respectively [8] Market Context - The reliance on international markets presents both opportunities and challenges for The Cooper Companies, making the analysis of international revenue trends crucial for future forecasts [9] - Analysts are closely monitoring these trends in the context of increasing global interdependencies and geopolitical tensions, which can impact earnings predictions [10]

Group 1 - The firm Needham raised the price target on Cooper Companies (COO) to $101 from $99 while maintaining a Buy rating on the shares [1] - Cooper Companies' Q1 results indicate a solid start to the year, with improvements in end markets [1] - The company is experiencing solid operating efficiencies, contributing to margin expansion and earnings upside [1]

Financial Performance - For the first quarter of fiscal 2026, Cooper Companies reported net sales of $695.1 million, an 8% increase compared to $646.1 million in the same period of fiscal 2025[97]. - For the three months ended January 31, 2026, total net sales increased by 3% to $329.0 million compared to $318.6 million in the same period of 2025, driven by a 6% increase in Fertility sales and a 2% increase in Office and surgical sales[109]. - Operating income rose by 17% to $212.8 million, representing 21% of net sales, compared to $182.0 million or 19% of net sales in 2025[118]. - Cash provided by operating activities increased to $260.9 million from $190.6 million in the prior year, driven by higher net income and improved operating capital[127]. Sales Growth - Toric and multifocal lenses generated $351.2 million in sales, reflecting a 10% growth from $319.4 million in the prior year, while spherical and other lenses saw a 5% increase to $343.9 million from $326.7 million[97]. - The Americas region contributed $289.0 million in sales, a 7% increase, while EMEA sales rose 15% to $282.3 million, driven by market gains in silicone hydrogel contact lenses[102]. Expenses and Margins - Consolidated gross margin remained flat at 68% for both the three months ended January 31, 2026, and January 31, 2025[110]. - Selling, General and Administrative (SGA) expenses increased by 1% to $390.2 million, representing 38% of net sales, compared to $387.9 million or 40% of net sales in 2025[111]. - Research and Development (R&D) expenses increased by 9% to $44.3 million, accounting for 4% of net sales, compared to $40.7 million in 2025[114]. Shareholder Actions - The company repurchased 1.1 million shares for $92.5 million at an average price of $82.04 per share during the three months ended January 31, 2026, with $873.9 million remaining authorized for repurchase[133]. Tax and Debt - The effective tax rate slightly decreased to 31.9% for the three months ended January 31, 2026, compared to 32.0% in the same period of 2025[124]. - Interest expense decreased by 14% to $22.4 million, primarily due to lower average debt balances[121]. - Working capital decreased to $538.1 million as of January 31, 2026, from $993.6 million as of October 31, 2025, primarily due to an increase in short-term debt[126]. Market and Product Development - CooperVision's MiSight 1 day lens received regulatory approvals in both China and Japan, enhancing its market presence in Asia[86]. - CooperSurgical's diversified portfolio includes products for fertility and women's health care, with a focus on in vitro fertilization and related services[88]. - The company anticipates long-term growth in the contact lens and health care markets, despite facing significant risks from global economic conditions and regulatory changes[85]. - CooperVision's single-use silicone hydrogel products, including MyDay and Biofinity, are expected to see increasing demand as the market shifts towards this modality[87]. - The company is focused on expanding its market presence through new product introductions and acquisitions in both existing and emerging markets[86]. - Cooper Companies emphasizes the importance of technological innovation and patent protection to maintain its competitive position in the market[90]. Foreign Exchange and Interest Rate Risks - Favorable foreign exchange rate fluctuations positively impacted sales by approximately $28.1 million during the quarter[100]. - A hypothetical 10% increase or decrease in foreign currency exchange rates would result in a corresponding increase or decrease of approximately $34.9 million in operating income for the fiscal quarter ended January 31, 2026[141]. - The majority of the company's total indebtedness remains subject to US-based variable interest rate risk tied to changes in the federal funds rate and SOFR[142]. - Interest rate fluctuations will impact the company's realized gain or loss, with a 1% change in interest rates not having a material impact on quarterly interest expense after considering interest rate swap contracts[143].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves navigating volatility and inherent risks [1] Group 1: Company Overview - The Cooper Companies (COO) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company specializes in surgical and contact lens products, making it a strong candidate for growth investment [3] Group 2: Earnings Growth - The historical EPS growth rate for The Cooper Companies is 6.6%, but projected EPS growth for this year is expected to be 9.4%, surpassing the industry average of 6.3% [4] Group 3: Cash Flow Growth - The Cooper Companies has a year-over-year cash flow growth of 7.9%, which is above the industry average of 7.5% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 9.5%, compared to the industry average of 6.7% [6] Group 4: Earnings Estimate Revisions - Current-year earnings estimates for The Cooper Companies have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [7] - This positive trend in earnings estimate revisions contributes to the company's Zacks Rank of 2 [8] Group 5: Investment Potential - The combination of a strong growth profile and positive earnings revisions positions The Cooper Companies as a potential outperformer and a solid choice for growth investors [9]

Company Overview - The Cooper Companies is a global medical device company with two main segments: CooperVision (CVI) and CooperSurgical (CSI) [11] - CVI focuses on contact lenses, particularly in daily silicone hydrogel lenses, torics, multifocals, and myopia management, with flagship products like MyDay and MiSight [11] - CSI provides products and services in fertility and women's health, including in-vitro fertilization (IVF) solutions and contraceptives [11] Investment Ratings - COO is rated 2 (Buy) on the Zacks Rank, indicating a positive outlook for the stock [12] - The company has a VGM Score of B, suggesting a favorable combination of value, growth, and momentum characteristics [12] Growth Potential - COO has a Growth Style Score of B, forecasting year-over-year earnings growth of 9.5% for the current fiscal year [12] - An analyst has revised their earnings estimate upwards for fiscal 2026, with the Zacks Consensus Estimate increasing to $4.51 per share [12] - The company has an average earnings surprise of +4.1%, indicating strong performance relative to expectations [12] Investment Recommendation - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, COO is recommended for investors' consideration [13]